Cite
HARVARD Citation
Murakami, T. et al. (2021). Oncological outcomes of dose reductions in cisplatin due to renal dysfunction for patients with metastatic urothelial carcinoma. BJUI Compass. 2 (5), pp. 322-330. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Murakami, T. et al. (2021). Oncological outcomes of dose reductions in cisplatin due to renal dysfunction for patients with metastatic urothelial carcinoma. BJUI Compass. 2 (5), pp. 322-330. [Online].